EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment

Jingjing Xue, Peng Chu, Wenjuan Gao, Furong Wang, Yuan Gao, Shuqing Liu, Zhijie Kang, Jinsong Yan, Haina Wang

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.07.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Jingjing Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Second Hospital of Dalian Medical University, Dalian, …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dalian Medical University, National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a heterogeneous disease and about one third of AML patients carry nucleophosmin (NPM1) mutation. Because 95% mutations give NPM1 an additional nuclear export signaling (NES) and dislocate NPM1 in cytoplasm (NPMc+), relocating NPM1 in nucleus provide an innovative strategy for treating this type of AML. The nuclear export of NPM1 depends on the nuclear protein export receptor XPO1, which recognizes the NES sequence on NPM1. Homoharringtonine (HHT) is a first-line chemotherapy drug of AML, yet the exact mechanism of its anti-AML activity is elusive. In this study, we found that HHT can directly target XPO1 to its NES-binding cleft, bind to Cys528 of XPO1, and inhibits its nuclear transport function. In addition, HHT can block NPMc+ proteins nuclear export and thus make NPMc+ AML cells much more sensitive to HHT treatment. Furthermore, the sensitivity of NPMc+ AML cells to HHT is a universal phenomenon irrespective of the different genetic lesions of AML. Taken together, our findings suggest that XPO1 is a new target of HHT and provide a novel strategy for NPMc+ AML treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansHomoharringtonineNuclear ProteinsCell NucleusCytoplasmMutation

Stichwörter der Autor:innen

AMLHomoharringtonineNPM1Nuclear export signalXPO1

Substanzen

HomoharringtonineNuclear Proteins

Autor:innen und Institutionen

  • Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Second Hospital of Dalian Medical University, Dalian, China; Department of Hematology, Liaoning Medical Center for Hematopoi…
  • College of Pharmacy, Dalian Medical University, Dalian, China.
  • Department of Biotechnology, Dalian Medical University, Dalian, China.
  • Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Second Hospital of Dalian Medical University, Dalian, China.
  • Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Second Hospital of Dalian Medical University, Dalian, China.
  • Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Second Hospital of Dalian Medical University, Dalian, China. Electronic address: kangzhijie2013@163.com.

Förderung

  • Dalian Medical University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Liaoning Province

Zitieren

APA

Xue, J., Chu, P., Gao, W., Wang, F., Gao, Y., Liu, S., Kang, Z., Yan, J., & Wang, H. (2023). XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.07.027

Vancouver

Xue J, Chu P, Gao W, Wang F, Gao Y, Liu S, et al. XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.07.027

BibTeX
@article{Xue2023,
  author = {Xue, Jingjing and Chu, Peng and Gao, Wenjuan and Wang, Furong and Gao, Yuan and Liu, Shuqing and Kang, Zhijie and Yan, Jinsong and Wang, Haina},
  title = {XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.07.027}
}
Kostenlos starten →